Expression and epigenetic regulation of angiogenesis-related factors during dormancy and recurrent growth of ovarian carcinoma

Epigenetics

Volumn 8, Issue 12, 2013, Pages 1330-1346

  Lyu, Tianjiao ^a   Jia, Nan ^a   Wang, Jieyu ^a   Yan, Xiaohui ^a   Yu, Yinhua ^a,b   Lu, Zhen ^b   Bast Jr, Robert C ^b   Hua, Keqin ^a   Feng, Weiwei ^a  

^a FUDAN UNIVERSITY   (China)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Angiogenesis; Dormancy; Histone modification; Methylation; Ovarian cancer; Recurrence

Indexed keywords

COMPLEMENTARY DNA; UVOMORULIN;

ACETYLATION; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOPHAGY; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DORMANCY; DOWN REGULATION; EPIGENETICS; FLOW CYTOMETRY; HISTONE MODIFICATION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; OVARY CARCINOMA; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TUMOR VOLUME; WESTERN BLOTTING; XENOGRAFT;

ANGIOGENESIS; DORMANCY; HISTONE MODIFICATION; METHYLATION; OVARIAN CANCER; RECURRENCE;

ACETYLATION; ANIMALS; AUTOPHAGY; CELL LINE, TUMOR; CELL PROLIFERATION; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HETEROGRAFTS; HISTONES; HUMANS; MICE; MICE, NUDE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM TRANSPLANTATION; NEOPLASMS, GLANDULAR AND EPITHELIAL; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; PROMOTER REGIONS, GENETIC;

EID: 84888811617     PISSN: 15592294     EISSN: 15592308     Source Type: Journal    
DOI: 10.4161/epi.26675     Document Type: Article

References (40)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62:10-29; PMID:22237781; http://dx.doi.org/10.3322/ caac.20138
2. Aguirre-Ghiso JA. Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer 2007; 7:834-46; PMID:17957189; http://dx.doi. org/10.1038/nrc2256
3. Almog N. Molecular mechanisms underlying tumor dormancy. Cancer Lett 2010; 294:139-46; PMID:20363069; http://dx.doi.org/10.1016/j. canlet.2010.03.004
4. Páez D, Labonte MJ, Bohanes P, Zhang W, Benhanim L, Ning Y, Wakatsuki T, Loupakis F, Lenz HJ. Cancer dormancy: a model of early dissemination and late cancer recurrence. Clin Cancer Res 2012; 18:645-53; PMID:22156560; http://dx.doi.org/10.1158/1078-0432.CCR-11-2186
5. Gilead A, Neeman M. Dynamic remodeling of the vascular bed precedes tumor growth: MLS ovarian carcinoma spheroids implanted in nude mice. Neoplasia 1999; 1:226-30; PMID:10935477; http:// dx.doi.org/10.1038/sj.neo.7900032
6. Wu X, Liang L, Dong L, Yu Z, Fu X. Effect of ARHI on lung cancer cell proliferation, apoptosis and invasion in vitro. Mol Biol Rep 2013; 40:2671-8; http://dx.doi.org/10.1007/s11033-012-2353-x; PMID:23247805
7. Wang Y, Yu Q, Cho AH, Rondeau G, Welsh J, Adamson E, Mercola D, McClelland M. Survey of differentially methylated promoters in prostate cancer cell lines. Neoplasia 2005; 7:748-60; PMID:16207477; http://dx.doi.org/10.1593/ neo.05289
8. Dalai I, Missiaglia E, Barbi S, Butturini G, Doglioni C, Falconi M, Scarpa A. Low expression of ARHI is associated with shorter progression-free survival in pancreatic endocrine tumors. Neoplasia 2007; 9:181-3; PMID:17401457; http://dx.doi.org/10.1593/ neo.06838
9. Rosen DG, Wang L, Jain AN, Lu KH, Luo RZ, Yu Y, Liu J, Bast RC Jr. Expression of the tumor suppressor gene ARHI in epithelial ovarian cancer is associated with increased expression of p21WAF1/CIP1 and prolonged progression-free survival. Clin Cancer Res 2004; 10:6559-66; PMID:15475444; http://dx.doi. org/10.1158/1078-0432.CCR-04-0698
10. Wang L, Hoque A, Luo RZ, Yuan J, Lu Z, Nishimoto A, Liu J, Sahin AA, Lippman SM, Bast RC Jr., et al. Loss of the expression of the tumor suppressor gene ARHI is associated with progression of breast cancer. Clin Cancer Res 2003; 9:3660-6; PMID:14506155
11. Yu Y, Xu F, Peng H, Fang X, Zhao S, Li Y, Cuevas B, Kuo WL, Gray JW, Siciliano M, et al. NOEY2 (ARHI), an imprinted putative tumor suppressor gene in ovarian and breast carcinomas. Proc Natl Acad Sci U S A 1999; 96:214-9; PMID:9874798; http://dx.doi.org/10.1073/pnas.96.1.214
12. Feng W, Marquez RT, Lu Z, Liu J, Lu KH, Issa JP, Fishman DM, Yu Y, Bast RC Jr. Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation. Cancer 2008; 112:1489-502; PMID:18286529; http://dx.doi.org/10.1002/cncr.23323
13. Feng W, Shen L, Wen S, Rosen DG, Jelinek J, Hu X, Huan S, Huang M, Liu J, Sahin AA, et al. Correlation between CpG methylation profiles and hormone receptor status in breast cancers. Breast Cancer Res 2007; 9:R57; PMID:17764565; http://dx.doi. org/10.1186/bcr1762
14. Fujii S, Luo RZ, Yuan J, Kadota M, Oshimura M, Dent SR, Kondo Y, Issa JP, Bast RC Jr., Yu Y. Reactivation of the silenced and imprinted alleles of ARHI is associated with increased histone H3 acetylation and decreased histone H3 lysine 9 methylation. Hum Mol Genet 2003; 12:1791-800; PMID:12874100; http://dx.doi.org/10.1093/hmg/ ddg204
15. Hisatomi H, Nagao K, Wakita K, Kohno N. ARHI/NOEY2 inactivation may be important in breast tumor pathogenesis. Oncology 2002; 62:136-40; PMID:11914599; http://dx.doi. org/10.1159/000048259
16. Yu Y, Fujii S, Yuan J, Luo RZ, Wang L, Bao J, Kadota M, Oshimura M, Dent SR, Issa JP, et al. Epigenetic regulation of ARHI in breast and ovarian cancer cells. Ann N Y Acad Sci 2003; 983:268-77; PMID:12724231; http://dx.doi. org/10.1111/j.1749-6632.2003.tb05981.x
17. Yuan J, Luo RZ, Fujii S, Wang L, Hu W, Andreeff M, Pan Y, Kadota M, Oshimura M, Sahin AA, et al. Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers. Cancer Res 2003; 63:4174-80; PMID:12874023
18. Lu Z, Luo RZ, Peng H, Rosen DG, Atkinson EN, Warneke C, Huang M, Nishmoto A, Liu J, Liao WS, et al. Transcriptional and posttranscriptional downregulation of the imprinted tumor suppressor gene ARHI (DRAS3) in ovarian cancer. Clin Cancer Res 2006; 12:2404-13; PMID:16638845; http://dx.doi. org/10.1158/1078-0432.CCR-05-1036
19. Luo RZ, Fang X, Marquez R, Liu SY, Mills GB, Liao WS, Yu Y, Bast RC. ARHI is a Ras-related small G-protein with a novel N-terminal extension that inhibits growth of ovarian and breast cancers. Oncogene 2003; 22:2897-909; PMID:12771940; http://dx.doi.org/10.1038/sj.onc.1206380
20. Badgwell DB, Lu Z, Le K, Gao F, Yang M, Suh GK, Bao JJ, Das P, Andreeff M, Chen W, et al. The tumorsuppressor gene ARHI (DIRAS3) suppresses ovarian cancer cell migration through inhibition of the Stat3 and FAK/Rho signaling pathways. Oncogene 2012; 31:68-79; PMID:21643014; http://dx.doi. org/10.1038/onc.2011.213
21. Lu Z, Luo RZ, Lu Y, Zhang X, Yu Q, Khare S, Kondo S, Kondo Y, Yu Y, Mills GB, et al. The tumor suppressor gene ARHI regulates autophagy and tumor dormancy in human ovarian cancer cells. J Clin Invest 2008; 118:3917-29; PMID:19033662
22. Albini A, Fontanini G, Masiello L, Tacchetti C, Bigini D, Luzzi P, Noonan DM, Stetler-Stevenson WG. Angiogenic potential in vivo by Kaposi's sarcoma cell-free supernatants and HIV-1 tat product: inhibition of KS-like lesions by tissue inhibitor of metalloproteinase-2. AIDS 1994; 8:1237-44; PMID:7528513; http://dx.doi. org/10.1097/00002030-199409000-00004
23. Almog N, Ma L, Raychowdhury R, Schwager C, Erber R, Short S, Hlatky L, Vajkoczy P, Huber PE, Folkman J, et al. Transcriptional switch of dormant tumors to fast-growing angiogenic phenotype. Cancer Res 2009; 69:836-44; PMID:19176381; http://dx.doi.org/10.1158/0008-5472.CAN-08-2590
24. Ehrlich M. DNA methylation in cancer: too much, but also too little. Oncogene 2002; 21:5400-13; PMID:12154403; http://dx.doi.org/10.1038/ sj.onc.1205651
25. Anand-Apte B, Bao L, Smith R, Iwata K, Olsen BR, Zetter B, Apte SS. A review of tissue inhibitor of metalloproteinases-3 (TIMP-3) and experimental analysis of its effect on primary tumor growth. Biochem Cell Biol 1996; 74:853-62; PMID:9164653; http://dx.doi.org/10.1139/o96-090
26. Qi JH, Ebrahem Q, Moore N, Murphy G, Claesson-Welsh L, Bond M, Baker A, Anand-Apte B. A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. Nat Med 2003; 9:407-15; PMID:12652295; http://dx.doi. org/10.1038/nm846
27. Pedrazzani C, Corso G, Marrelli D, Roviello F. E-cadherin and hereditary diffuse gastric cancer. Surgery 2007; 142:645-57; PMID:17981184; http:// dx.doi.org/10.1016/j.surg.2007.06.006
28. Pinheiro H, Carvalho J, Oliveira P, Ferreira D, Pinto MT, Osório H, Licastro D, Bordeira-Carriço R, Jordan P, Lazarevic D, et al. Transcription initiation arising from E-cadherin/CDH1 intron2: a novel protein isoform that increases gastric cancer cell invasion and angiogenesis. Hum Mol Genet 2012; 21:4253-69; PMID:22752307; http://dx.doi. org/10.1093/hmg/dds248
29. Yi Kim D, Kyoon Joo J, Kyu Park Y, Yeob Ryu S, Soo Kim H, Kyun Noh B, Hwa Lee K, Hyuk Lee J. E-cadherin expression in early gastric carcinoma and correlation with lymph node metastasis. J Surg Oncol 2007; 96:429-35; PMID:17786966; http://dx.doi. org/10.1002/jso.20732
30. Jiménez B, Volpert OV, Crawford SE, Febbraio M, Silverstein RL, Bouck N. Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat Med 2000; 6:41-8; PMID:10613822; http://dx.doi.org/10.1038/71517
31. Wendt MK, Taylor MA, Schiemann BJ, Schiemann WP. Down-regulation of epithelial cadherin is required to initiate metastatic outgrowth of breast cancer. Mol Biol Cell 2011; 22:2423-35; PMID:21613543; http://dx.doi.org/10.1091/mbc. E11-04-0306
32. Mack GS. Epigenetic cancer therapy makes headway. J Natl Cancer Inst 2006; 98:1443-4; PMID:17047192; http://dx.doi.org/10.1093/jnci/ djj447
33. Thompson CA. Vorinostat approved for rare lymphoma. Am J Health Syst Pharm 2006; 63:2168; PMID:17090730; http://dx.doi.org/10.2146/ news060020
34. Chen MY, Liao WS, Lu Z, Bornmann WG, Hennessey V, Washington MN, Rosner GL, Yu Y, Ahmed AA, Bast RC Jr. Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy. Cancer 2011; 117:4424-38; PMID:21491416; http://dx.doi. org/10.1002/cncr.26073
35. Hellebrekers DM, Jair KW, Viré E, Eguchi S, Hoebers NT, Fraga MF, Esteller M, Fuks F, Baylin SB, van Engeland M, et al. Angiostatic activity of DNA methyltransferase inhibitors. Mol Cancer Ther 2006; 5:467-75; PMID:16505122; http://dx.doi. org/10.1158/1535-7163.MCT-05-0417
36. Kim MS, Kwon HJ, Lee YM, Baek JH, Jang JE, Lee SW, Moon EJ, Kim HS, Lee SK, Chung HY, et al. Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med 2001; 7:437-43; PMID:11283670; http://dx.doi. org/10.1038/86507
37. Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell 2012; 150:12-27; PMID:22770212; http://dx.doi.org/10.1016/j. cell.2012.06.013
38. Shinojima T, Yu Q, Huang SK, Li M, Mizuno R, Liu ET, Hoon DS, Lessard L. Heterogeneous epigenetic regulation of TIMP3 in prostate cancer. Epigenetics 2012; 7:1279-89; PMID:23023649; http://dx.doi. org/10.4161/epi.22333
39. Pesta M, Kulda V, Topolcan O, Safranek J, Vrzalova J, Cerny R, Holubec L. Significance of methylation status and the expression of RECK mRNA in lung tissue of patients with NSCLC. Anticancer Res 2009; 29:4535-9; PMID:20032402
40. Barski D, Wolter M, Reifenberger G, Riemenschneider MJ. Hypermethylation and transcriptional downregulation of the TIMP3 gene is associated with allelic loss on 22q12.3 and malignancy in meningiomas. Brain Pathol 2010; 20:623-31; PMID:19922547; http://dx.doi. org/10.1111/j.1750-3639.2009.00340.x